Price
No data yet.
Social Signal Score
Revenue
$98.7KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dane Stevens
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 6
- Beta
- 1.59
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.16
Financials
Revenue
$98.7K+1137.2%Net Income
$-1.69MEBITDA
$-1.34MFree Cash Flow
$-2.02MEPS (diluted)
$-0.39Shares Outstanding (diluted)
4.30M+87.6%Operating Expenses
$758.4KCash & Debt
$9.20MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $426.9K | $-3.72M | $-1.16 |
| 2024 | $389.9K | $-6.04M | $-2.02 |
| 2023 | $181.1K | $-5.19M | $-1.79 |
| 2022 | $80.7K | $-7.35M | $-2.70 |
| 2021 | $0.00 | $-6.02M | $-0.12 |
| 2020 | $0.00 | $-507.7K | $-1.12 |
Valuation
OPTHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Neutral
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027
View source ↗
Earnings
Tue, Feb 2(in 5 months)
Consensus estimate $-0.13 per share
Typical surprise -88.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.40 vs $-0.26miss
- Mon, Jun 1$-0.35 vs $-0.19miss
- Tue, Feb 17$-0.35 vs $-0.19miss
Estimates and results for OPTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in OPTH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.